Is Innova Captab overvalued or undervalued?

As of 4 November 2025, the valuation grade for Innova Captab has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 36.20, an EV to EBITDA of 25.34, and a ROE of 13.37%. In comparison to its peers, Sun Pharma has a PE of 35.41 and an EV to EBITDA of 24.02, while Cipla, rated as attractive, shows a significantly lower PE of 22.35 and an EV to EBITDA of 5.59.
Despite the recent stock performance showing a 1.48% return over the past week against a -1.38% return for the Sensex, the year-to-date performance of Innova Captab is concerning at -25.63%, indicating potential overvaluation in the longer term. Overall, the current valuation metrics suggest that while Innova Captab is not undervalued, it is positioned fairly within its industry.